WinRHO is an immunomodulator used to prevent Rh factor insensitivity in pregnant women with Rh-negative blood type. It helps prevent the formation of antibodies that might attack the fetus's blood cells if the fetus has Rh-positive blood, thus protecting the pregnancy from complications such as fetal anemia or stillbirth. This medication is usually given in the 28th week of pregnancy and after birth if the fetus is Rh-positive.
WinRHO is also used to treat some cases of thrombocytopenia resulting from immune dysfunction. It works by reducing platelet breakdown by modifying the immune system's response, leading to an increase in platelet counts and a reduced risk of bleeding. It should be used under close medical supervision, with monitoring after injection to avoid any unwanted reactions and maintain patient safety throughout the treatment period.